Nicolle Lindsay, Anderson Peter A M, Conly John, Mainprize Thomas C, Meuser Jamie, Nickel J Curtis, Senikas Vyta M, Zhanel George G
University of Manitoba, Winnipeg.
Can Fam Physician. 2006 May;52(5):612-8.
To review treatment recommendations for empiric therapy of uncomplicated urinary tract infection (uUTI) in light of evolving antibiotic resistance and to consider use of guidelines to promote optimal practice.
PubMed was searched and additional relevant references were identified by reviewing articles found in the search. Guidelines were identified through discussion with family practitioners. Level of evidence was assessed for recommendations.
Many women have uUTIs. The treatment approach is usually empiric antimicrobial therapy without obtaining pretherapy cultures. Trimethoprim-sulfamethoxazole is standard first-line empiric treatment. While resistance to this drug is increasing, it remains only about 10% in community-acquired Escherichia coli in Canada. Concerns about increased resistance have contributed to greater use of fluoroquinolones, but widespread empiric use of this class of medications might promote resistance to fluoroquinolones. Hence, fluoroquinolones should not be considered first-line therapy. While guidelines for treatment of uUTIs have been developed, their usefulness is compromised by their conflicting recommendations.
Trimethoprim-sulfamethoxazole and nitrofurantoin remain first-choice empiric therapy for uUTIs. Development of guidelines relevant to family physicians and community education programs that incorporate local susceptibility patterns are important strategies for promoting optimal practice.
鉴于抗生素耐药性不断演变,回顾单纯性尿路感染(uUTI)经验性治疗的推荐方案,并考虑利用指南来促进最佳实践。
检索了PubMed,并通过查阅检索中找到的文章确定了其他相关参考文献。通过与家庭医生讨论确定了指南。对推荐意见的证据水平进行了评估。
许多女性患有uUTI。治疗方法通常是经验性抗菌治疗,无需进行治疗前培养。复方新诺明是标准的一线经验性治疗药物。虽然对该药的耐药性在增加,但在加拿大社区获得性大肠杆菌中,耐药率仍仅约为10%。对耐药性增加的担忧导致氟喹诺酮类药物的使用增多,但这类药物的广泛经验性使用可能会促进对氟喹诺酮类药物产生耐药性。因此,氟喹诺酮类药物不应被视为一线治疗药物。虽然已经制定了uUTI的治疗指南,但其有用性因相互矛盾的推荐意见而受到影响。
复方新诺明和呋喃妥因仍然是uUTI经验性治疗的首选药物。制定与家庭医生相关的指南以及纳入当地药敏模式的社区教育项目是促进最佳实践的重要策略。